Inventor

SCHWARZ HANS-PETER

AT119 patents

⚠️ This page may combine multiple inventors who share the name “SCHWARZ HANS-PETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SCHWARZ HANS-PETER

BAXTER AG

Pharmaceutical preparation for treating blood coagulation disorders

Factor IX/factor IXa activating antibodies and antibody derivatives

Stable preparation for the treatment of blood coagulation disorders

Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use

Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Immunotolerant prothrombin complex preparation

Stable blood coagulation inhibitor-free factor vii preparation and method for preparing same

Method for isolation of highly pure von willebrand factor

Pharmaceutical preparation comprising vWF propeptide

Devices and methods for removing pathogens from biological fluids

Pharmaceutical preparation for treating blood coagulation disorders

Pharmaceutical preparation for treating blood coagulation disorders

Pharmaceutical preparation for treating blood coagulation disorders

BAXALTA INC

Stabilized liquid and lyophilized ADAMTS13 formulations

Removal of serine proteases by treatment with finely divided silicon dioxide

Removal of serine proteases by treatment with finely divided silicon dioxide

Stabilized liquid and lyophilized ADAMTS13 formulations

Methods of measuring adamts 13 activity

Stabilized liquid and lyophilized ADAMTS13 formulations

Stabilized liquid and lyophilized ADAMTS13 formulations

Methods of measuring ADAMTS 13 activity

Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

IMMUNO AG

Pharmaceutical preparation for treating blood coagulation disorders

Method for isolation of highly pure von Willebrand Factor

Use of von willebrand factor and pharmaceutical formulation

Stable preparation for the treatment of blood coagulation disorders

Method for isolation of highly pure von willebrand factor

Thrombosis agent

BAXTER INT

Method for testing treatment of ADAMTS13 deficiency

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Method to produce an immunoglobulin preparation with improved yield

TESCHNER WOLFGANG

Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Removal of serine proteases by treatment with finely divided silicon dioxide

TAKEDA PHARMACEUTICALS CO

Recombinant VWF formulations

Method to produce an immunoglobulin preparation with improved yield

WEBER ALFRED

Methods for differentiating plasma-derived protein from recombinant protein in a sample

Modification-dependent activity assays

IMMUNO AKTIENGESLLSCHAFT

Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use

STORZ KARL GMBH & CO

Flexible endoscope

SANQUIN BLOEDVOORZIENING

Factor VII polypeptide having factor VII:C activity

MATTHIESSEN PETER

Stabilized liquid and lyophilized ADAMTS13 formulations

BAIRSTOW SHAWN F

Manufacture of factor H (FH) and FH-derivatives from plasma

BAXTER INNOVATIONS GMBH

Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

BRUCKSCHWAIGER LEOPOLD

Method to produce an immunoglobulin preparation with improved yield

SCHWARZ HANS-PETER

Modified recombinant factor VIII and von Willebrand factor and methods of use